Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a...

Full description

Bibliographic Details
Main Authors: Chaoyue Zhang, Yangtao Lin, Qianjin Kuang, Hongjin Li, Qilong Jiang, Xiaojun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Immunology
Subjects:
myasthenia gravis
telitacicept
efgartigimod
highly active
refractory
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400459/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400459/full

Similar Items